Trials / Completed
CompletedNCT02151695
Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.
Phase 2 Study of Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Poitiers University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Proliferative diabetic retinopathy is a serious complication of diabetes mellitus, partly consecutive to upregulation of vascular endothelial growth factor (VEGF) as a consequence of retinal ischemia leads. Aflibercept has been approved by FDA and European medicine agency for treatment of exudative age-related macular degeneration, another retinal disease characterized by choroidal new vessels. The aim of this pilot study is to evaluate the efficacy and the safety of Aflibercept intravitreal injections compared to panretinal photocoagulation for proliferative diabetic retinopathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | panretinal photocoagulation | |
| DRUG | Aflibercept intravitreal injections |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2018-10-31
- Completion
- 2020-03-06
- First posted
- 2014-05-30
- Last updated
- 2020-03-10
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02151695. Inclusion in this directory is not an endorsement.